H

Hbm Holdings Ltd
HKEX:2142

Watchlist Manager
Hbm Holdings Ltd
HKEX:2142
Watchlist
Price: 12.71 HKD -5.43% Market Closed
Market Cap: 11.1B HKD

Gross Margin
Hbm Holdings Ltd

93%
Current
96%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
93%
=
Gross Profit
107.6m
/
Revenue
115.7m

Gross Margin Across Competitors

No Stocks Found

Hbm Holdings Ltd
Glance View

Market Cap
10.1B HKD
Industry
Biotechnology

HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.

Intrinsic Value
4.42 HKD
Overvaluation 65%
Intrinsic Value
Price
H
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
93%
=
Gross Profit
107.6m
/
Revenue
115.7m
What is the Gross Margin of Hbm Holdings Ltd?

Based on Hbm Holdings Ltd's most recent financial statements, the company has Gross Margin of 93%.

Back to Top